Panel wants regulations for genetic tests

Jan 18, 2008

A federal panel contended that regulations for genetic testing have not advanced with the growing number of consumers who buy them.

The panel, named the Secretary's Advisory Committee on Genetics, Health and Society, argued that the increasing amount of genetic trials have been advertised with unproved claims and could be deceptive, The New York Times reported Friday. The panel is part of the Department of Health and Human Services.

Cancer, diabetes, heart failure, and cystic fibrosis are among the conditions the tests claim to inform at risk patients of.

The panel warns that inaccurate test results given by doctors who lack experience with them could cause harm to sick patients in need of correct treatment.

"We would welcome more federal regulation. It's unclear what regulatory requirements apply to our products," Sciona Chief Science Officer, Rosalynn D. Gill said of the company, which conducts "nutrigenetic tests" over the internet.

The panel wrote in a report that test providers lack requirements for information disclosure to support their claims and that proof of their value is rare.

Copyright 2008 by United Press International

Explore further: Amgen misses 1Q views as higher costs cut profit

add to favorites email to friend print save as pdf

Related Stories

What you need to know about GMOS and GM crops

Jan 20, 2014

Genetically modified (GM) crops and foods and ingredients made available with the techniques of modern biotechnology have recently been dominating food and agriculture news coverage in the United States. Food Technology ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

17 hours ago

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

High-calorie and low-nutrient foods in kids' TV

Fruits and vegetables are often displayed in the popular Swedish children's TV show Bolibompa, but there are also plenty of high-sugar foods. A new study from the University of Gothenburg explores how food is portrayed in ...

Male-biased tweeting

Today women take an active part in public life. Without a doubt, they also converse with other women. In fact, they even talk to each other about other things besides men. As banal as it sounds, this is far ...